Research

Denmark dumps J&J vaccine from anti-Covid arsenal

Share
U.S. pauses use of Johnson & Johnson vaccine over blood clot reports News18 days ago7:34

Ultimately, federal health officials decided that Johnson & Johnson's one-and-done vaccine is critical to fighting the pandemic - and that the small clot risk could be handled with warnings to help younger women decide if they should use that shot or an alternative.

Johnson & Johnson is already a household name due to products like Band-Aid, Tylenol and Baby Shampoo.

The single-shot vaccine is critical to Allen County's efforts to bring shots to vulnerable and hard-to-reach populations, as the shot only requires one dose and can be stored at normal temperatures that make it easier to transport.

For reasons linked to extremely rare blood clotting issues, the AstraZeneca and Johnson & Johnson vaccines are only being given to patients aged over 55.

France began administering the J&J vaccine on 24 April.

Emergent announced earlier this month that 15 million doses of the latter had been ruined by cross-contamination - a development that prompted the White House to put Johnson & Johnson in charge of the facility.

The Danish weekly CPHPost quoted Professor Jan Pravsgaard Christensen from the Department of Immunology and Microbiology at the University of Copenhagen as saying that if only Pfizer and Moderna (the only vaccines allowed by Danish authorities) are to be applied, the last group "will have to wait until Christmas". The US Food and Drug Administration (FDA) has since ordered the facility to stop making more J&J vaccines until it addresses the violations and manufacturing errors, which resulted in 15 millions of those doses being destroyed, the report said.

The World Health Organization and European medicines watchdog have both authorised the J&J vaccine.

The pause came at an inconvenient time for Allen County Public Health, which had recently started a mass vaccination effort at the former Knights of Columbus Hall that relied on the single-dose shot to inoculate hundreds of people per day.

Health Canada says it is seeking information from the FDA and J&J's pharmaceutical arm, Janssen, to determine if the 300,000 doses shipped to Canada meet required safety standards.

Share